TY - JOUR
T1 - Attention Deficit Hyperactivity Disorder in Preschool Children
AU - Greenhill, Laurence L.
AU - Posner, Kelly
AU - Vaughan, Brigette S.
AU - Kratochvil, Christopher J.
N1 - Funding Information:
Dr. Greenhill has received support from Celltech, Cephalon, Eli Lilly, Janssen, McNeil, Medeva, Novartis Corporation, Noven, Otsuka, Pfizer, Sanofi, Shire, Solvay, Somerset, and Thompson Advanced Therapeutics Communications. As part of an effort to help execute the FDA suicidality classification mandates, Dr. Posner has received funding from the FDA to develop and implement the suicidality classification system used in their child antidepressant safety analyses. This system was subsequently used in the adult antidepressant safety analyses. As part of an effort to help execute the FDA suicidality classification mandates, Dr. Posner has had research support from Abbott, Bristol Myers Squibb, Organon, Schwarz, GlaxoSmithKline, Eli Lilly, Johnson and Johnson, Wyeth Research, Sanofi-Aventis, Cephalon, Novartis, Shire Pharmaceuticals, Merck, Pfizer and Vivus. Dr. Kratochvil has received support from Cephalon, Eli Lilly, McNeil, Abbott, Pfizer, Shire, Somerset, and AstraZeneca.
PY - 2008/4
Y1 - 2008/4
N2 - Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder with a childhood onset of symptoms and impairment. Although it is most frequently identified during elementary school years, epidemiologic data suggest that the onset of ADHD frequently occurs earlier, with presentation as young as 3 years of age. Early identification, however, allows consideration of appropriate interventions. Many data are available on safe and efficacious treatment options for school-aged children who have ADHD; however, little is known about the use of these modalities in preschoolers and, ultimately, the long-term effects of early treatment. Recognition of the preschool presentation of ADHD, appropriate differential diagnosis, and identification of comorbid conditions, and a developmental perspective on the course and potential outcomes of the disorder may guide treatment planning. Newly available data on the safety and efficacy of pharmacotherapy and psychosocial intervention for preschoolers who have ADHD may help clinicians make treatment decisions for these young children and their families.
AB - Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder with a childhood onset of symptoms and impairment. Although it is most frequently identified during elementary school years, epidemiologic data suggest that the onset of ADHD frequently occurs earlier, with presentation as young as 3 years of age. Early identification, however, allows consideration of appropriate interventions. Many data are available on safe and efficacious treatment options for school-aged children who have ADHD; however, little is known about the use of these modalities in preschoolers and, ultimately, the long-term effects of early treatment. Recognition of the preschool presentation of ADHD, appropriate differential diagnosis, and identification of comorbid conditions, and a developmental perspective on the course and potential outcomes of the disorder may guide treatment planning. Newly available data on the safety and efficacy of pharmacotherapy and psychosocial intervention for preschoolers who have ADHD may help clinicians make treatment decisions for these young children and their families.
UR - http://www.scopus.com/inward/record.url?scp=39149088667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39149088667&partnerID=8YFLogxK
U2 - 10.1016/j.chc.2007.11.004
DO - 10.1016/j.chc.2007.11.004
M3 - Review article
C2 - 18295150
AN - SCOPUS:39149088667
VL - 17
SP - 347
EP - 366
JO - Child and Adolescent Psychiatric Clinics of North America
JF - Child and Adolescent Psychiatric Clinics of North America
SN - 1056-4993
IS - 2
ER -